Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 3/2012

01-05-2012 | Review

The role of sialic acid as a modulator of the anti-inflammatory activity of IgG

Authors: Sybille Böhm, Inessa Schwab, Anja Lux, Falk Nimmerjahn

Published in: Seminars in Immunopathology | Issue 3/2012

Login to get access

Abstract

Immunoglobulin G (IgG) molecules can have two completely opposing activities. They can be very potent pro-inflammatory mediators on the one hand, directing the effector functions of the innate immune system towards infected cells, tumor cells or healthy tissues in the case of autoimmune diseases. On the other hand, a mixture of IgG molecules purified from the blood of ten thousands of healthy donors is used as an anti-inflammatory treatment for many autoimmune diseases since several decades. It has become evident only recently that certain residues in the sugar moiety attached to the IgG constant fragment can dramatically alter the pro- and anti-inflammatory activities of IgG. This review will focus on sialic acid residues as a modulator of the anti-inflammatory activity and provide an overview of situations where serum IgG glycosylation and sialylation is altered and which molecular and cellular pathways may be involved in this immunomodulatory pathway.
Literature
1.
Nimmerjahn F, Ravetch JV (2010) Antibody-mediated modulation of immune responses. Immunol Rev 236:265–275PubMedCrossRef
2.
Takai T (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2(8):580–592PubMed
3.
Hogarth PM (2002) Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 14(6):798–802PubMedCrossRef
4.
5.
Ravetch JV, Clynes RA (1998) Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 16:421–432PubMedCrossRef
6.
Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A (2011) An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19(1):101–113. doi:10.​1016/​j.​ccr.​2010.​11.​012 PubMedCrossRef
7.
8.
Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101–104. doi:10.​1038/​nature06106 PubMedCrossRef
9.
10.
11.
Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV (1999) Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 189(1):179–185PubMedCrossRef
12.
Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203(3):789–797, Epub 2006 Mar 2006PubMedCrossRef
13.
14.
15.
Bolland S, Ravetch JV (2000) Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13(2):277–285PubMedCrossRef
16.
17.
18.
Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787):670–673PubMedCrossRef
19.
Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591–6604PubMedCrossRef
20.
Walker MR, Lund J, Thompson KM, Jefferis R (1989) Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259(2):347–353PubMed
21.
Lund J, Tanaka T, Takahashi N, Sarmay G, Arata Y, Jefferis R (1990) A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol Immunol 27(11):1145–1153PubMedCrossRef
22.
Tao MH, Morrison SL (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143(8):2595–2601PubMed
23.
Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325(5):979–989PubMedCrossRef
24.
Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R (2000) The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 37(12–13):697–706PubMedCrossRef
25.
Ghetie V, Ward ES (2000) Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 18:739–766PubMedCrossRef
26.
Mori K, Iida S, Yamane-Ohnuki N, Kanda Y, Kuni-Kamochi R, Nakano R, Imai-Nishiya H, Okazaki A, Shinkawa T, Natsume A, Niwa R, Shitara K, Satoh M (2007) Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. Cytotechnology 55(2–3):109–114. doi:10.​1007/​s10616-007-9103-2 PubMedCrossRef
27.
28.
Natsume A, Niwa R, Satoh M (2009) Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 3:7–16PubMed
29.
Crow AR, Brinc D, Lazarus AH (2009) New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost 7(Suppl 1):245–248PubMedCrossRef
30.
31.
Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27(3):233–245PubMedCrossRef
32.
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50PubMedCrossRef
33.
34.
Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA (2001) Glycosylation and the immune system. Science 291(5512):2370–2376PubMedCrossRef
35.
36.
Sutton BJ, Phillips DC (1983) The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G. Biochem Soc Trans 11(2):130–132
37.
38.
Masuda K, Yamaguchi Y, Kato K, Takahashi N, Shimada I, Arata Y (2000) Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Lett 473(3):349–357PubMedCrossRef
39.
Holland M, Yagi H, Takahashi N, Kato K, Savage CO, Goodall DM, Jefferis R (2006) Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 1760(4):669–677. doi:10.​1016/​j.​bbagen.​2005.​11.​021 PubMedCrossRef
40.
Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA (1997) Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 36(6):1370–1380. doi:10.​1021/​bi9621472 PubMedCrossRef
41.
42.
Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 157(11):4963–4969PubMed
43.
Mimura Y, Ashton PR, Takahashi N, Harvey DJ, Jefferis R (2007) Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J Immunol Methods 326(1–2):116–126. doi:10.​1016/​j.​jim.​2007.​07.​014 PubMedCrossRef
44.
Sondermann P, Huber R, Oosthuizen V, Jacob U (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406(6793):267–273PubMedCrossRef
45.
46.
Deisenhofer J (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 20(9):2361–2370PubMedCrossRef
47.
Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K et al (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316(6027):452–457PubMedCrossRef
48.
Sumar N, Isenberg DA, Bodman KB, Soltys A, Young A, Leak AM, Round J, Hay FC, Roitt IM (1991) Reduction in IgG galactose in juvenile and adult onset rheumatoid arthritis measured by a lectin binding method and its relation to rheumatoid factor. Ann Rheum Dis 50(9):607–610PubMedCrossRef
49.
Parekh RB, Roitt IM, Isenberg DA, Dwek RA, Ansell BM, Rademacher TW (1988) Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1(8592):966–969PubMedCrossRef
50.
Young A, Sumar N, Bodman K, Goyal S, Sinclair H, Roitt I, Isenberg D (1991) Agalactosyl IgG: an aid to differential diagnosis in early synovitis. Arthritis Rheum 34(11):1425–1429PubMedCrossRef
51.
Lu MC, Hsieh SC, Lai NS, Li KJ, Wu CH, Yu CL (2007) Comparison of anti-agalactosyl IgG antibodies, rheumatoid factors, and anti-cyclic citrullinated peptide antibodies in the differential diagnosis of rheumatoid arthritis and its mimics. Clin Exp Rheumatol 25(5):716–721.PubMed
52.
Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, Haupl T, Burmester GR, Deelder AM, Huizinga TW, Wuhrer M, Toes RE (2010) Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62(6):1620–1629. doi:10.​1002/​art.​27414 PubMedCrossRef
53.
Leirisalo-Repo M, Hernandez-Munoz HE, Rook GA (1999) Agalactosyl IgG is elevated in patients with active spondyloarthropathy. Rheumatol Int 18(5–6):171–176PubMedCrossRef
54.
Tomana M, Schrohenloher RE, Koopman WJ, Alarcon GS, Paul WA (1988) Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum 31(3):333–338PubMedCrossRef
55.
Keusch J, Levy Y, Shoenfeld Y, Youinou P (1996) Analysis of different glycosylation states in IgG subclasses. Clin Chim Acta 252(2):147–158PubMedCrossRef
56.
Dube R, Rook GA, Steele J, Brealey R, Dwek R, Rademacher T, Lennard-Jones J (1990) Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. Gut 31(4):431–434PubMedCrossRef
57.
Holland M, Takada K, Okumoto T, Takahashi N, Kato K, Adu D, Ben-Smith A, Harper L, Savage CO, Jefferis R (2002) Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clin Exp Immunol 129(1):183–190PubMedCrossRef
58.
van de Geijn FE, Wuhrer M, Selman MH, Willemsen SP, de Man YA, Deelder AM, Hazes JM, Dolhain RJ (2009) Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther 11(6):R193PubMedCrossRef
59.
Rook GA, Steele J, Brealey R, Whyte A, Isenberg D, Sumar N, Nelson JL, Bodman KB, Young A, Roitt IM et al (1991) Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun 4(5):779–794PubMedCrossRef
60.
Pasek M, Duk M, Podbielska M, Sokolik R, Szechinski J, Lisowska E, Krotkiewski H (2006) Galactosylation of IgG from rheumatoid arthritis (RA) patients–changes during therapy. Glycoconj J 23(7–8):463–471. doi:10.​1007/​s10719-006-5409-0 PubMedCrossRef
61.
Croce A, Firuzi O, Altieri F, Eufemi M, Agostino R, Priori R, Bombardieri M, Alessandri C, Valesini G, Saso L (2007) Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 21(5):303–314. doi:10.​1002/​jcla.​20191 PubMedCrossRef
62.
Wang J, Balog CI, Stavenhagen K, Koeleman CA, Scherer HU, Selman MH, Deelder AM, Huizinga TW, Toes RE, Wuhrer M (2011) Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 10(5):M110 004655. doi:10.​1074/​mcp.​M110.​004655 PubMed
63.
Bond A, Cooke A, Hay FC (1990) Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis. Eur J Immunol 20(10):2229–2233PubMedCrossRef
64.
Kuroda Y, Nakata M, Hirose S, Shirai T, Iwamoto M, Izui S, Kojima N, Mizuochi T (2001) Abnormal IgG galactosylation in MRL-lpr/lpr mice: pathogenic role in the development of arthritis. Pathol Int 51(12):909–915PubMedCrossRef
65.
Kuroda Y, Nakata M, Nose M, Kojima N, Mizuochi T (2001) Abnormal IgG galactosylation and arthritis in MRL-Fas(lpr) or MRL-FasL(gld) mice are under the control of the MRL genetic background. FEBS Lett 507(2):210–214PubMedCrossRef
66.
Rook G, Thompson S, Buckley M, Elson C, Brealey R, Lambert C, White T, Rademacher T (1991) The role of oil and agalactosyl IgG in the induction of arthritis in rodent models. Eur J Immunol 21(4):1027–1032. doi:10.​1002/​eji.​1830210425 PubMedCrossRef
67.
Mehta AS, Long RE, Comunale MA, Wang M, Rodemich L, Krakover J, Philip R, Marrero JA, Dwek RA, Block TM (2008) Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 82(3):1259–1270. doi:10.​1128/​JVI.​01600-07 PubMedCrossRef
68.
Parekh R, Isenberg D, Rook G, Roitt I, Dwek R, Rademacher T (1989) A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun 2(2):101–114PubMedCrossRef
69.
Wuhrer M, Porcelijn L, Kapur R, Koeleman CA, Deelder A, de Haas M, Vidarsson G (2009) Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res 8(2):450–456. doi:10.​1021/​pr800651j PubMedCrossRef
70.
Omtvedt LA, Royle L, Husby G, Sletten K, Radcliffe CM, Harvey DJ, Dwek RA, Rudd PM (2006) Glycan analysis of monoclonal antibodies secreted in deposition disorders indicates that subsets of plasma cells differentially process IgG glycans. Arthritis Rheum 54(11):3433–3440. doi:10.​1002/​art.​22171 PubMedCrossRef
71.
Axford JS (1988) Decreased B-cell galactosyltransferase activity in rheumatoid arthritis. Br J Rheumatol 27(Suppl 2):170PubMed
72.
Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T (1988) Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 167(5):1731–1736PubMedCrossRef
73.
Yamada E, Tsukamoto Y, Sasaki R, Yagyu K, Takahashi N (1997) Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J 14(3):401–405PubMedCrossRef
74.
Shikata K, Yasuda T, Takeuchi F, Konishi T, Nakata M, Mizuochi T (1998) Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J 15(7):683–689PubMedCrossRef
75.
Ruhaak LR, Uh HW, Beekman M, Koeleman CA, Hokke CH, Westendorp RG, Wuhrer M, Houwing-Duistermaat JJ, Slagboom PE, Deelder AM (2010) Decreased levels of bisecting GlcNAc glycoforms of IgG are associated with human longevity. PLoS One 5(9):e12566. doi:10.​1371/​journal.​pone.​0012566 PubMedCrossRef
76.
Rademacher TW, Williams P, Dwek RA (1994) Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA 91(13):6123–6127PubMedCrossRef
77.
Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB (1995) Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1(3):237–243PubMedCrossRef
78.
Hadley AG, Zupanska B, Kumpel BM, Pilkington C, Griffiths HL, Leader KA, Jones J, Booker DJ, Stamps R, Sokol RJ (1995) The glycosylation of red cell autoantibodies affects their functional activity in vitro. Br J Haematol 91(3):587–594PubMedCrossRef
79.
Kumpel BM, Rademacher TW, Rook GA, Williams PJ, Wilson IB (1994) Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas 5(3–4):143–151PubMed
80.
Kumpel BM, Wang Y, Griffiths HL, Hadley AG, Rook GA (1995) The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Hum Antibodies Hybridomas 6(3):82–88PubMed
81.
Boyd PN, Lines AC, Patel AK (1995) The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32(17–18):1311–1318PubMedCrossRef
82.
83.
Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D (2002) Arthritis critically dependent on innate immune system players. Immunity 16(2):157–168PubMedCrossRef
84.
Carroll MC (1998) The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 16:545–568PubMedCrossRef
85.
Ghirlando R, Lund J, Goodall M, Jefferis R (1999) Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett 68(1):47–52PubMedCrossRef
86.
87.
van de Geijn FE, de Man YA, Wuhrer M, Willemsen SP, Deelder AM, Hazes JM, Dolhain RJ (2011) Mannose-binding lectin does not explain the course and outcome of pregnancy in rheumatoid arthritis. Arthritis Res Ther 13(1):R10. doi:10.​1186/​ar3231 PubMedCrossRef
88.
Garred P, Madsen HO, Marquart H, Hansen TM, Sorensen SF, Petersen J, Volck B, Svejgaard A, Graudal NA, Rudd PM, Dwek RA, Sim RB, Andersen V (2000) Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheumatol 27(1):26–34PubMed
89.
Graudal NA, Madsen HO, Tarp U, Svejgaard A, Jurik G, Graudal HK, Garred P (2000) The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 43(3):515–521. doi:10.1002/1529-0131(200003)43:3<515::AID-ANR6>3.0.CO;2-TPubMedCrossRef
90.
Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, Rispens T (2011) Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 6(6):e21246. doi:10.​1371/​journal.​pone.​0021246 PubMedCrossRef
91.
Stadlmann J, Weber A, Pabst M, Anderle H, Kunert R, Ehrlich HJ, Peter Schwarz H, Altmann F (2009) A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 9(17):4143–4153PubMedCrossRef
92.
Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320(5874):373–376PubMedCrossRef
93.
Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44(7):1524–1534PubMedCrossRef
94.
Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291(5503):484–486PubMedCrossRef
95.
Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18(4):573–581PubMedCrossRef
96.
Crow AR, Song S, Freedman J, Helgason CD, Humphries RK, Siminovitch KA, Lazarus AH (2003) IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102(2):558–560PubMedCrossRef
97.
Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. doi:10.​1038/​nature10134
98.
Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lunemann JD (2009) Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA 106(12):4788–4792. doi:10.​1073/​pnas.​0807319106 PubMedCrossRef
99.
Anthony RM, Wermeling F, Karlsson MC, Ravetch JV (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 105(50):19571–19578PubMedCrossRef
100.
Granelli-Piperno A, Pritsker A, Pack M, Shimeliovich I, Arrighi JF, Park CG, Trumpfheller C, Piguet V, Moran TM, Steinman RM (2005) Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol 175(7):4265–4273PubMed
101.
Soilleux EJ, Morris LS, Leslie G, Chehimi J, Luo Q, Levroney E, Trowsdale J, Montaner LJ, Doms RW, Weissman D, Coleman N, Lee B (2002) Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol 71(3):445–457PubMed
102.
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH (2006) Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12(6):688–692, Epub 2006 May 2021PubMedCrossRef
103.
Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24(1):19–28PubMedCrossRef
104.
Pricop L, Redecha P, Teillaud JL, Frey J, Fridman WH, Sautes-Fridman C, Salmon JE (2001) Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 166(1):531–537PubMed
105.
Crow AR, Song S, Semple JW, Freedman J, Lazarus AH (2007) A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 109(1):155–158PubMedCrossRef
Metadata
Title
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG
Authors
Sybille Böhm
Inessa Schwab
Anja Lux
Falk Nimmerjahn
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 3/2012
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-012-0308-x

Other articles of this Issue 3/2012

Seminars in Immunopathology 3/2012 Go to the issue

Introduction

Introduction for the Special Issue on Glycosylation and Immunity

Review Article

Myeloproliferation and hematopoietic stem cell dysfunction due to defective Notch receptor modification by O-fucose glycans

Review

Glycosylation of IgA1 and pathogenesis of IgA nephropathy

Review

Sialoadhesin in recognition of self and non-self

Review

Roles for major histocompatibility complex glycosylation in immune function

Review Article

Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits